Clinical Trials Browser

Non Small Cell Lung Cancer NSCLC × durvalumab × 30 days × Clear all

NCT03164616 2026-03-13

POSEIDON

Phase 3 Active not recruiting

1,186 enrolled 26 charts 1 FDA

Non Small Cell Lung Cancer NSCLC